×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Endocannabinoid System Modulation Therapy
therapeutic
1,979 words
KG: Endocannabinoid System Modulation Therapy
2026-03-31
section:therapeutics
kind:therapeutic-approach
state:published
therapeutic-target:endocannabinoid-system
disease:alzheimers-disease
disease:parkinsons-disease
disease:amyotrophic-lateral-sclerosis
disease:huntingtons-disease
disease:frontotemporal-dementia
Contents
Endocannabinoid System Modulation Therapy
💊
Therapeutic Info
Name
Endocannabinoid System Modulation Therapy
Summary
Comprehensive therapeutic approach targeting the endocannabinoid system (CB1/CB2 receptors, anandamide, 2-AG) for neurodegenerative diseases including AD, PD, ALS, HD, and FTD
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Conversion Therapy
Score: 0.44
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
PARP1 Inhibition Therapy
Score: 0.58
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Blood-Brain Barrier SPM Shuttle System
Score: 0.55
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Vagal Afferent Microbial Signal Modulation
Score: 0.52
Epigenetic Memory Erasure via TET2 Activation
Score: 0.52
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
Astroglial Gap Junction Coordination via Connexin-43 Phospho
Score: 0.50
Ganglioside Rebalancing Therapy
Score: 0.50
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.49
Microglial Purinergic Reprogramming
Score: 0.48
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.48
Complement C1q Mimetic Decoy Therapy
Score: 0.48
RNA Granule Nucleation Site Modulation
Score: 0.48
Show 25 more
Related Analyses (28)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 23 more
Related Experiments (14)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40
Show 9 more
Key Papers (1)
Proposed symptom-based model of the origins of schizophrenia.
Medical hypotheses 2020
See Also (10)
LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy
clinical · Pages share 4 hypotheses
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for
clinical · Pages share 4 hypotheses
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 4 hypotheses
UPenn Observational Research Repository (NCT04715399)
clinical · Pages share 3 hypotheses
remternetug-anti-amyloid-alzheimers
clinical_trial · Pages share 3 hypotheses
ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT
clinical · Pages share 3 hypotheses
A Phase 2 Double-Blind, Randomized, Placebo-Controlled
clinical · Pages share 3 hypotheses
nct05508789
clinical_trial · Pages share 3 hypotheses
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-
clinical · Pages share 3 hypotheses
Adipose-Derived Mesenchymal Stem Cell Therapy for Early
clinical · Pages share 3 hypotheses
Show 5 more